R

Raydiant Oximetry Inc

Source from Raydiant Oximetry Inc

Send an enquiry directly.

About Raydiant Oximetry Inc

Raydiant Oximetry is a clinical-stage medical device company developing innovative fetal monitoring technologies to improve maternal and neonatal outcomes during childbirth. The company's flagship product, Lumerah, is a non-invasive fetal pulse oximeter that measures fetal arterial blood oxygen saturation using biophotonics and machine learning—addressing a…

Read full company overview

Raydiant Oximetry is a clinical-stage medical device company developing innovative fetal monitoring technologies to improve maternal and neonatal outcomes during childbirth. The company's flagship product, Lumerah, is a non-invasive fetal pulse oximeter that measures fetal arterial blood oxygen saturation using biophotonics and machine learning—addressing a critical clinical need where current electronic fetal monitoring is associated with high false-positive rates and unnecessary cesarean deliveries. Lumerah has received FDA Breakthrough Device designation and completed a 35-patient Early Feasibility Study. The company also develops Daisy, a surgical device designed to quantify blood loss and prevent postpartum hemorrhage after cesarean sections. Raydiant Oximetry collaborates with GE HealthCare and has secured substantial funding including a $5.6 million Series A round and grants from the Bill & Melinda Gates Foundation and March of Dimes Innovation Fund. The company is positioned to reduce maternal and neonatal mortality while decreasing unnecessary emergency cesarean deliveries through evidence-based fetal oxygenation monitoring.

Company information is compiled from public sources and may be out of date. It is not an endorsement or medical advice.

Products (2)

Other products · 02
  • —

    Lumerah

    Non-invasive fetal pulse oximeter using biophotonics and machine learning to directly measure fetal arterial blood oxygen saturation (SpO2). Preclinical data shows improved sensitivity and specificity for detecting fetal distress. FDA Breakthrough Device designated. Completed 35-patient Early Feasibility Study; IDE Pilot Study underway at LSU Health Shreveport.

    Request quote
  • —

    Daisy

    Surgical device designed to quantify blood loss and prevent postpartum hemorrhage following cesarean sections, addressing a major cause of maternal mortality.

    Request quote

Send an Enquiry

Optional unless you tick "Phone" or "WhatsApp" below.

Best ways to reach you (pick all that work)

Or contact directly

www.raydiantoximetry.com
info@raydiantoximetry.com
+1 650-822-7762
2603 Camino Ramon, San Ramon, California, United States, 94583

Need a structured price?

Submit an RFP to compare Raydiant Oximetry Inc alongside up to 4 other vendors. Sealed responses, side-by-side at the deadline.

Submit an RFP